丹参酮IIA (Tanshinone IIA, TanIIA)是从中药丹参中提取的主要有效成分之一,研究表明其在抗炎、抗氧化、抗肿瘤、心脏保护及神经系统保护方面具有显著的药理活性。本文采用文献计量学的方法,对国内外有关丹参酮IIA的研究进行分析,发现...丹参酮IIA (Tanshinone IIA, TanIIA)是从中药丹参中提取的主要有效成分之一,研究表明其在抗炎、抗氧化、抗肿瘤、心脏保护及神经系统保护方面具有显著的药理活性。本文采用文献计量学的方法,对国内外有关丹参酮IIA的研究进行分析,发现丹参酮IIA的研究是基于2000年至2024年间发表的13,681篇有关丹参酮IIA的文献的计量学分析;该领域发表研究论文最多的国家是中国,美国和澳大利亚,而发表论文最多的机构为中国医科大学,中国科学院和中山大学。丹参酮IIA在心血管疾病和神经系统疾病中的研究文献占比最高,研究类型主要以应用基础研究,临床研究和技术开发为主,出现频率最多的关键词为凋亡,表达,激活,氧化应激,炎症反应等,体现了其在这些领域的研究热度和临床应用价值。丹参酮IIA作为一种具有多重药理活性的中药成分,显示出广泛的临床应用前景,而当前研究的局限性和挑战需要我们在未来的研究中予以重视,通过多学科合作和创新研究方法,共同推动丹参酮IIA在疾病治疗中的进一步应用与发展。Tanshinone IIA (TanIIA) is one of the main active ingredients extracted from the traditional Chinese medicine Danshen, and studies have shown that it has significant pharmacological activities in anti-inflammatory, antioxidant, anti-tumor, cardioprotective and nervous system protection. In this paper, bibliometric methods were used to analyze the studies on tanshinone IIA at home and abroad, and found that the research on tanshinone IIA was based on quantitative analysis of 13,681 articles on tanshinone IIA published between 2000 and 2024. The countries with the most published research papers in this field are China, United States and Australia, while the institutions with the most published papers are China Medical University, Chinese Academy of Sciences and Sun Yat-sen University. Tanshinone IIA has the highest proportion of research literature in cardiovascular diseases and nervous system diseases, and the research types are mainly applied basic research, clinical research and technology development, and the most frequent keywords are apoptosis, expression, activation, oxidative stress, inflammatory response, etc., reflecting its research enthusiasm and clinical application value in these fields. As a traditional Chinese medicine ingredient with multiple pharmacological activities, tanshinone IIA has shown a wide range of clinical application prospects, but the limitations and challenges of current research need to be paid attention to in future research, and jointly promote the further application and development of tanshinone IIA in disease treatment through multidisciplinary cooperation and innovative research methods.展开更多
目的:系统评价丹参川芎嗪注射液联合西医常规治疗急性脑梗死的有效性和安全性。方法:计算机检索中国知网(CNKI)、万方、维普、中国生物医学文献数据库(CBM)、PubMed、Web of Science、和EMbase等数据库,收集建库至2022年5月31日有关丹...目的:系统评价丹参川芎嗪注射液联合西医常规治疗急性脑梗死的有效性和安全性。方法:计算机检索中国知网(CNKI)、万方、维普、中国生物医学文献数据库(CBM)、PubMed、Web of Science、和EMbase等数据库,收集建库至2022年5月31日有关丹参川芎嗪联合西医常规治疗急性脑梗死的临床随机对照试验。采用《Cochrane干预措施系统评价手册》对纳入的研究进行质量评价,采用RevMan 5.4软件进行Meta分析。结果:共纳入16项研究,涉及1693例病人。Meta分析结果显示,与对照组比较,试验组美国国立卫生研究院卒中量表(NIHSS)评分降低[MD=-3.75,95%CI(-5.46,-2.05),P<0.0001],临床总有效率[RR=1.20,95%CI(1.15,1.25),P<0.00001]、日常生活活动能力[MD=10.39,95%CI(8.94,11.83),P<0.00001]提高,血小板聚集率[MD=-15.31,95%CI(-20.23,-10.40),P<0.00001]、纤维蛋白原[MD=-0.86,95%CI(-1.39,-0.32),P=0.002]、血浆黏度[MD=-0.34,95%CI(-0.55,-0.13),P=0.002]降低。两组不良反应发生率比较,差异无统计学意义[RR=1.35,95%CI(0.62,2.88),P=0.44]。结论:现有证据表明,在西医常规治疗基础上联用丹参川芎嗪注射液治疗急性脑梗死可提高临床疗效,但纳入文献质量不高,需更多的多中心随机对照试验支持。展开更多
文摘丹参酮IIA (Tanshinone IIA, TanIIA)是从中药丹参中提取的主要有效成分之一,研究表明其在抗炎、抗氧化、抗肿瘤、心脏保护及神经系统保护方面具有显著的药理活性。本文采用文献计量学的方法,对国内外有关丹参酮IIA的研究进行分析,发现丹参酮IIA的研究是基于2000年至2024年间发表的13,681篇有关丹参酮IIA的文献的计量学分析;该领域发表研究论文最多的国家是中国,美国和澳大利亚,而发表论文最多的机构为中国医科大学,中国科学院和中山大学。丹参酮IIA在心血管疾病和神经系统疾病中的研究文献占比最高,研究类型主要以应用基础研究,临床研究和技术开发为主,出现频率最多的关键词为凋亡,表达,激活,氧化应激,炎症反应等,体现了其在这些领域的研究热度和临床应用价值。丹参酮IIA作为一种具有多重药理活性的中药成分,显示出广泛的临床应用前景,而当前研究的局限性和挑战需要我们在未来的研究中予以重视,通过多学科合作和创新研究方法,共同推动丹参酮IIA在疾病治疗中的进一步应用与发展。Tanshinone IIA (TanIIA) is one of the main active ingredients extracted from the traditional Chinese medicine Danshen, and studies have shown that it has significant pharmacological activities in anti-inflammatory, antioxidant, anti-tumor, cardioprotective and nervous system protection. In this paper, bibliometric methods were used to analyze the studies on tanshinone IIA at home and abroad, and found that the research on tanshinone IIA was based on quantitative analysis of 13,681 articles on tanshinone IIA published between 2000 and 2024. The countries with the most published research papers in this field are China, United States and Australia, while the institutions with the most published papers are China Medical University, Chinese Academy of Sciences and Sun Yat-sen University. Tanshinone IIA has the highest proportion of research literature in cardiovascular diseases and nervous system diseases, and the research types are mainly applied basic research, clinical research and technology development, and the most frequent keywords are apoptosis, expression, activation, oxidative stress, inflammatory response, etc., reflecting its research enthusiasm and clinical application value in these fields. As a traditional Chinese medicine ingredient with multiple pharmacological activities, tanshinone IIA has shown a wide range of clinical application prospects, but the limitations and challenges of current research need to be paid attention to in future research, and jointly promote the further application and development of tanshinone IIA in disease treatment through multidisciplinary cooperation and innovative research methods.
文摘目的:系统评价丹参川芎嗪注射液联合西医常规治疗急性脑梗死的有效性和安全性。方法:计算机检索中国知网(CNKI)、万方、维普、中国生物医学文献数据库(CBM)、PubMed、Web of Science、和EMbase等数据库,收集建库至2022年5月31日有关丹参川芎嗪联合西医常规治疗急性脑梗死的临床随机对照试验。采用《Cochrane干预措施系统评价手册》对纳入的研究进行质量评价,采用RevMan 5.4软件进行Meta分析。结果:共纳入16项研究,涉及1693例病人。Meta分析结果显示,与对照组比较,试验组美国国立卫生研究院卒中量表(NIHSS)评分降低[MD=-3.75,95%CI(-5.46,-2.05),P<0.0001],临床总有效率[RR=1.20,95%CI(1.15,1.25),P<0.00001]、日常生活活动能力[MD=10.39,95%CI(8.94,11.83),P<0.00001]提高,血小板聚集率[MD=-15.31,95%CI(-20.23,-10.40),P<0.00001]、纤维蛋白原[MD=-0.86,95%CI(-1.39,-0.32),P=0.002]、血浆黏度[MD=-0.34,95%CI(-0.55,-0.13),P=0.002]降低。两组不良反应发生率比较,差异无统计学意义[RR=1.35,95%CI(0.62,2.88),P=0.44]。结论:现有证据表明,在西医常规治疗基础上联用丹参川芎嗪注射液治疗急性脑梗死可提高临床疗效,但纳入文献质量不高,需更多的多中心随机对照试验支持。
